Eli Lilly’s merestinib has seen its Phase Transition Success Rate (PTSR) drop after an investigator-led Phase II trial of the candidate in solid tumors was terminated.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,